[go: up one dir, main page]

MX2020010031A - Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d). - Google Patents

Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).

Info

Publication number
MX2020010031A
MX2020010031A MX2020010031A MX2020010031A MX2020010031A MX 2020010031 A MX2020010031 A MX 2020010031A MX 2020010031 A MX2020010031 A MX 2020010031A MX 2020010031 A MX2020010031 A MX 2020010031A MX 2020010031 A MX2020010031 A MX 2020010031A
Authority
MX
Mexico
Prior art keywords
methods
surfactant protein
oligomers
systems
characterizing
Prior art date
Application number
MX2020010031A
Other languages
English (en)
Inventor
Mark Cornell Manning
Jan Susan Rosenbaum
Ryan R Manning
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2020010031A publication Critical patent/MX2020010031A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/02—Investigating particle size or size distribution
    • G01N15/0205—Investigating particle size or size distribution by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
    • G01N21/53—Scattering, i.e. diffuse reflection within a body or fluid within a flowing fluid, e.g. smoke
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/0005—Field flow fractionation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N2021/4704—Angular selective
    • G01N2021/4711—Multiangle measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)

Abstract

Algunas modalidades de los métodos y composiciones proporcionadas en este documento incluyen identificar y/o cuantificar especies oligoméricas de proteína surfactante D (SP-D). Algunas modalidades incluyen llevar a cabo un fraccionamiento asimétrico del campo-flujo del flujo con análisis de dispersión de luz láser de múltiples ángulos (AF4-MALLS) en la SP-D.
MX2020010031A 2018-03-29 2019-03-27 Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d). MX2020010031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650138P 2018-03-29 2018-03-29
PCT/US2019/024320 WO2019191254A1 (en) 2018-03-29 2019-03-27 Systems and methods for characterizing surfactant protein d (sp-d) oligomers

Publications (1)

Publication Number Publication Date
MX2020010031A true MX2020010031A (es) 2021-01-08

Family

ID=68058505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010031A MX2020010031A (es) 2018-03-29 2019-03-27 Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).

Country Status (15)

Country Link
US (1) US12385894B2 (es)
EP (1) EP3773675B1 (es)
JP (2) JP7798475B2 (es)
KR (1) KR102731267B1 (es)
CN (1) CN112218649A (es)
AU (1) AU2019243714B2 (es)
BR (1) BR112020019914A2 (es)
CA (1) CA3094966A1 (es)
ES (1) ES2999367T3 (es)
IL (1) IL277469B2 (es)
MX (1) MX2020010031A (es)
PL (1) PL3773675T3 (es)
PT (1) PT3773675T (es)
RU (1) RU2020131641A (es)
WO (1) WO2019191254A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095043A1 (en) 2018-03-29 2019-10-03 Airway Therapeutics, Inc. Methods and compositions comprising surfactant protein d (sp-d)
WO2024195854A1 (ja) * 2023-03-23 2024-09-26 積水メディカル株式会社 肺サーファクタントプロテインｄの測定方法、測定キット、モノクローナル抗体及び細胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333041B1 (en) * 1998-03-02 2001-12-25 Children's Hospital Medical Center Nontoxic vernix compositions and method of producing
WO2007056195A2 (en) * 2005-11-03 2007-05-18 Children's Hospital Medical Center Surfactant protein-d for prevention and treatment of lung infections and sepsis
US6838428B2 (en) 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
JP4485062B2 (ja) 1998-11-19 2010-06-16 財団法人化学及血清療法研究所 細胞死抑制活性を有するペプチド断片
DK1440083T3 (da) 2001-10-25 2013-03-25 Medical Res Council Molekyler
US20050137126A1 (en) * 2003-04-09 2005-06-23 Natlmmune A/S Treatment of SARS in individuals
JP4744533B2 (ja) * 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
JP6002660B2 (ja) 2010-04-15 2016-10-05 ジェネンテック， インコーポレイテッド 抗ユビキチン抗体及び使用方法
DK2661308T3 (da) 2011-01-05 2019-08-12 Prenatal Int Gmbh Hypotonisk vandig sammensætning med reduceret chloridindhold med eller uden phospholipider
JP6390846B2 (ja) * 2011-11-11 2018-09-19 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチアナタバカムにおいて生成される血球凝集素を含むインフルエンザウイルス様粒子（ｖｌｐ）
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
JP6854530B2 (ja) 2016-02-16 2021-04-07 プレジデント アンド フェローズ オブ ハーバード カレッジ 病原体ワクチンならびにその製造および使用方法
CA3074288A1 (en) * 2017-09-06 2019-03-14 Airway Therapeutics, LLC Methods, compositions and cells for preparing surfactant protein d (sp-d)
CA3074280A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC Methods and compositions for preparing surfactant protein d (sp-d)
CA3095043A1 (en) 2018-03-29 2019-10-03 Airway Therapeutics, Inc. Methods and compositions comprising surfactant protein d (sp-d)

Also Published As

Publication number Publication date
CA3094966A1 (en) 2019-10-03
KR102731267B1 (ko) 2024-11-18
IL277469B2 (en) 2024-11-01
JP7798475B2 (ja) 2026-01-14
US12385894B2 (en) 2025-08-12
KR20200143405A (ko) 2020-12-23
AU2019243714B2 (en) 2025-01-02
IL277469B1 (en) 2024-07-01
CN112218649A (zh) 2021-01-12
EP3773675A1 (en) 2021-02-17
JP2021519918A (ja) 2021-08-12
PT3773675T (pt) 2025-01-07
US20210010988A1 (en) 2021-01-14
EP3773675B1 (en) 2024-12-04
PL3773675T3 (pl) 2025-03-03
ES2999367T3 (en) 2025-02-25
RU2020131641A (ru) 2022-04-29
AU2019243714A1 (en) 2020-10-15
JP2024069637A (ja) 2024-05-21
WO2019191254A1 (en) 2019-10-03
BR112020019914A2 (pt) 2021-01-05
IL277469A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
SG11202101934SA (en) Methods and systems for sample processing or analysis
EP3725067B8 (en) Method and system for identifying light source and application thereof
WO2019222523A3 (en) Methods for processing nucleic acid samples
AR123115A1 (es) Composiciones y métodos para la degradación selectiva de proteínas
EP3864392A4 (en) OPTICAL SAMPLE PROCESSING SYSTEMS AND METHODS
EP4018020A4 (en) SYSTEMS AND METHODS FOR PREDICTING PROTEINS
MX2017011933A (es) Sistema y metodo de desinfeccion con luz.
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
EP4545649A3 (en) Methods for processing nucleic acid samples
EP4010456A4 (en) SYSTEMS AND METHODS FOR SAMPLE PREPARATION, DATA GENERATION AND PROTEIN CORONA ANALYSIS
GB2553451A (en) Implementing a neural network algorithm on a neurosynaptic substrate based on metadata associated with the neural network algorithm
GB202020171D0 (en) Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
BR112017007654A2 (pt) sistemas e métodos para o imageamento de amostras de fluido
ZA202102344B (en) Method and system of identifying and quantifying a protein
IN2015DN02927A (es)
EP3784955A4 (en) ARRANGEMENTS, SYSTEMS AND METHODS FOR BALANCED SUSPENSION OF LAMPS
WO2019028470A3 (en) Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
MX2020010031A (es) Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).
TR201903963T4 (tr) Hizalama içermeyen sekans analizi kullanılarak bir hedef sekans içindeki mutasyon(lar)ı içeren üyeler için bir popülasyonun taranmasına ait yüksek verimlilik metodu.
MX2024011859A (es) Biomarcadores de arn para angioedema hereditario
WO2019139980A8 (en) Methods for measuring analyte and/or protein in biological samples
SG11202103841XA (en) Method for identifying an unknown biological sample from multiple attributes
ZA202102546B (en) Methods for identifying free thiols in proteins
SA518391425B1 (ar) طرق لاستخلاص حمض بدون خلية لفحص غير باضع قبل الولادة dna
EA202090380A1 (ru) Системы и способы для выполнения анализа гликанов в образце в режиме реального времени